Please login to the form below

Not currently logged in

GSK pay $3bn to settle drug-marketing case

UK drug-maker pleads guilty for promoting a number of drugs in the US off-label

Representing the highest healthcare fraud settlement in US history, GlaxoSmithKline (GSK) has agreed to pay $3bn (£1.9bn) for promoting a number of drugs in the US off-label.

The UK drug maker is to plead guilty for promoting antidepressants, Paxil and Wellbutrin, for unapproved uses, which includes the treatment of children.

GSK will also concede charges for withholding safety data and making unsupported safety claims concerning its diabetes drug Avandia.

The $3bn fine covers both criminal charges and civil settlements.

US deputy attorney general said at news conference in Washington that: “Today's multibillion-dollar settlement is unprecedented in both scope and size. It underscores this administration's firm commitment to protecting the American people and holding accountable those who commit healthcare fraud.”

The company has also been charged with paying kickbacks to doctors.

“The salesforce bribed physicians to prescribe GSK products using every imaginable form of high-priced entertainment, from Hawaiian vacations [and] paying doctors millions of dollars to go on speaking tours, to tickets to Madonna concerts," said US attorney Carmin Ortiz.

In a statement, GSK's chief executive Andrew Witty has said: “Today brings to a resolution difficult, long-standing matters for GSK. Whilst these originate in a different era for the company, they cannot and will not be ignored. On behalf of GSK, I want to express our regret and reiterate that we have learnt from the mistakes that were made.”

As part of the settlement agreement, GSK will be monitored by the US government for five years. 

3rd July 2012

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...